ABIVAX Société Anonyme (EPA:ABVX)
85.05
-1.15 (-1.33%)
Jun 19, 2026, 5:35 PM CET
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.34M EUR in the quarter ending March 31, 2026, with 35.21% growth. This brings the company's revenue in the last twelve months to 4.92M, down -59.82% year-over-year. In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M, down -63.22%.
Revenue (ttm)
4.92M
Revenue Growth
-59.82%
P/S Ratio
1,377.65
Revenue / Employee
61.50K
Employees
80
Market Cap
6.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.86M | -63.22% |
| Dec 31, 2024 | 12.43M | 7.85M | 171.67% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 156.33M |
| Genfit | 65.43M |
| Cellectis | 65.14M |
| Nanobiotix | 32.59M |
| MedinCell | 32.44M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
ABIVAX Société Anonyme News
- 3 days ago - ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 9 days ago - ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 11 days ago - ABVX DEADLINE: The Gross Law Firm Reminds ABIVAX Societe Anonyme Investors of Upcoming Securities Class Action Deadline - PRNewsWire
- 12 days ago - Abivax (ABVX) Faces Securities Fraud Investigation Amid Clinical Trial Concerns - GuruFocus
- 16 days ago - Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX) - Newsfile Corp
- 16 days ago - Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank - TheFly
- 16 days ago - Top Biotech Gainers: ABVX, CING, DRTS, MMED... - Nasdaq
- 17 days ago - This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead? - The Motley Fool